By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



One MedImmune Way

Gaithersburg  Maryland  20878  U.S.A.
Phone: 301-398-0000 Fax: 301-398-9000


MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.

With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.

Key Statistics

Ownership: Public

Web Site: MedImmune
Employees: 3,000
Symbol: AZN


Company News
Immunocore Starts Clinical Trial With IMCgp100 In Combination With MedImmune (AZN) Immunotherapies Durvalumab And Tremelimumab 1/20/2016 6:02:01 AM
Cepheid (CPHD) Announces Diagnostic Collaboration With MedImmune (AZN) And COMBACTE To Facilitate Clinical Trials Of New Monoclonal Antibodies To Prevent Serious Infectious Diseases 1/14/2016 7:01:06 AM
Rani Therapeutics Announces Collaboration With MedImmune (AZN) In The Metabolic Disease Field 1/6/2016 9:28:32 AM
Unilife  (UNIS) Signs Commercial Supply Agreement Wth MedImmune (AZN) 11/4/2015 7:34:24 AM
Igenica, Inc. Enters Into A Strategic Oncology Research Agreement With MedImmune (AZN) 10/28/2015 6:39:22 AM
Human Vaccines Project Partners With MedImmune (AZN) To Help Accelerate Research And Development In Infectious Disease And Oncology 10/13/2015 8:27:39 AM
MedImmune (AZN) And 3M Drug Delivery Systems Partner To Develop Novel TLR Agonist Cancer Therapies 9/25/2015 1:57:40 PM
MedImmune (AZN) And Tanabe Research Laboratories U.S.A., Inc./Mitsubishi Tanabe Enter Into Strategic Collaboration And Licensing Agreement For The Development Of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates To Treat Cancer 9/23/2015 1:52:15 PM
Former MedImmune (AZN) Oncology Head Joins Molecular Response as CEO 9/15/2015 7:24:36 AM
Advaxis, Inc. And MedImmune (AZN) Commence Enrollment In Phase I/II Study Of Axalimogene Filolisbac (ADXS-HPV) In Combination With Durvalumab (MEDI4736) For The Treatment Of HPV-Associated Cancers 8/20/2015 7:59:57 AM